$1.49
4.62% yesterday
Nasdaq, Dec 24, 08:47 pm CET
ISIN
US40423R1059
Symbol
HCWB

HCW Biologics Inc Stock price

$1.49
-0.69 31.57% 1M
-2.89 66.02% 6M
-16.36 91.68% YTD
-14.44 90.67% 1Y
-77.32 98.12% 3Y
-250.52 99.41% 5Y
-250.52 99.41% 10Y
-250.52 99.41% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.07 4.62%
ISIN
US40423R1059
Symbol
HCWB
Industry

Key metrics

Basic
Market capitalization
$4.0m
Enterprise Value
$9.7m
Net debt
$5.7m
Cash
$1.1m
Shares outstanding
2.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.3 | 0.6
EV/Sales
22.6 | 1.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-22.6%
Return on Equity
443.1%
ROCE
548.0%
ROIC
-
Debt/Equity
-3.2
Financials (TTM | estimate)
Revenue
$430.0k | $7.2m
EBITDA
$-10.7m | -
EBIT
$-11.0m | $-6.0m
Net Income
$-22.1m | $-12.3m
Free Cash Flow
$-13.1m
Growth (TTM | estimate)
Revenue
-87.7% | 178.3%
EBITDA
70.8% | -
EBIT
70.3% | 79.1%
Net Income
40.3% | 59.0%
Free Cash Flow
30.1%
Margin (TTM | estimate)
Gross
20.3%
EBITDA
-2,511.7% | -
EBIT
-2,570.4%
Net
-5,187.6% | -171.9%
Free Cash Flow
-3,074.6%
More
EPS
$-9.8
FCF per Share
$-5.0
Short interest
2.7%
Employees
36
Rev per Employee
$70.0k
Show more

Is HCW Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

HCW Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a HCW Biologics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a HCW Biologics Inc forecast:

Buy
86%
Hold
14%

Financial data from HCW Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.43 0.43
88% 88%
100%
- Direct Costs 0.34 0.34
86% 86%
79%
0.09 0.09
92% 92%
21%
- Selling and Administrative Expenses 7.47 7.47
75% 75%
1,737%
- Research and Development Expense - -
-
-
-11 -11
71% 71%
-2,491%
- Depreciation and Amortization 0.25 0.25
14% 14%
58%
EBIT (Operating Income) EBIT -11 -11
70% 70%
-2,549%
Net Profit -22 -22
40% 40%
-5,144%

In millions USD.

Don't miss a Thing! We will send you all news about HCW Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

HCW Biologics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE N...
Neutral
GlobeNewsWire
about one month ago
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, today reported financial results and recent business highlights for its third quarter ended Se...
Neutral
GlobeNewsWire
about 2 months ago
Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors
More HCW Biologics Inc News

Company Profile

HCW Biologics, Inc. operates as a holding company which engages in the research and development of immunotherapies. It focuses on cancer and aging-associated diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

Head office United States
CEO Hing Wong
Employees 36
Founded 2018
Website hcwbiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today